Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) EPS (Basic) (2020 - 2025)

Historic EPS (Basic) for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to -$0.31.

  • Fulcrum Therapeutics' EPS (Basic) rose 1142.86% to -$0.31 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.21, marking a year-over-year decrease of 31724.14%. This contributed to the annual value of -$156.9 for FY2024, which is 976763.07% down from last year.
  • Fulcrum Therapeutics' EPS (Basic) amounted to -$0.31 in Q3 2025, which was up 1142.86% from -$0.28 recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' EPS (Basic) registered a high of $0.89 during Q2 2024, and its lowest value of -$267.29 during Q4 2024.
  • For the 5-year period, Fulcrum Therapeutics' EPS (Basic) averaged around -$15.23, with its median value being -$0.45 (2022).
  • Data for Fulcrum Therapeutics' EPS (Basic) shows a peak YoY increase of 33421.05% (in 2024) and a maximum YoY decrease of 6672369.64% (in 2024) over the last 5 years.
  • Over the past 5 years, Fulcrum Therapeutics' EPS (Basic) (Quarter) stood at -$0.58 in 2021, then grew by 18.97% to -$0.47 in 2022, then grew by 14.89% to -$0.4 in 2023, then plummeted by 66723.7% to -$267.29 in 2024, then surged by 99.88% to -$0.31 in 2025.
  • Its EPS (Basic) stands at -$0.31 for Q3 2025, versus -$0.28 for Q2 2025 and -$267.29 for Q4 2024.